Potentiating CAR t against solid cancers

ICAM1-targeted chimeric costimulation robustly activates NFκB signaling in CAR or TCR pathways, enhancing T cell activation beyond what either receptor can achieve alone.

Inducible IL-12 achieves safe intratumoral delivery exclusively when paired with CAR T cells engineered for optimal affinity.

Patients receive both CAR T cells and nanobodies only after PET imaging confirms tumor-specific nanobody distribution. Delivery is carefully optimized to maximize therapeutic benefit while ensuring safety.